home / stock / spex / spex quote
Last: | $ |
---|---|
Change Percent: | -5.56% |
Open: | $1.0596 |
Close: | $0.9916 |
High: | $1.146 |
Low: | $0.951 |
Volume: | 73,879 |
Last Trade Date Time: | 02/12/2020 04:49:50 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $1.0596 | $0.9916 | $1.146 | $0.951 | 73,879 | 02-12-2020 |
$ | $1.04 | $1.05 | $1.0973 | $1.02 | 8,059 | 02-11-2020 |
$ | $1.02 | $1.058 | $1.058 | $1.02 | 27,241 | 02-10-2020 |
$ | $1.03 | $1.035 | $1.04 | $1.02 | 23,999 | 02-07-2020 |
$ | $1.08 | $1.02 | $1.08 | $1.02 | 13,835 | 02-06-2020 |
$ | $1.04 | $1.09 | $1.099 | $1.02 | 17,463 | 02-05-2020 |
$ | $1.12 | $1.04 | $1.12 | $1.03 | 16,819 | 02-04-2020 |
$ | $1.12 | $1.02 | $1.14 | $1.02 | 101,760 | 02-03-2020 |
$ | $1.18 | $1.1596 | $1.18 | $1.13 | 9,864 | 01-31-2020 |
$ | $1.16 | $1.1843 | $1.24 | $1.1353 | 19,240 | 01-30-2020 |
$ | $1.20 | $1.1752 | $1.20 | $1.1547 | 8,948 | 01-29-2020 |
$ | $1.167 | $1.1611 | $1.24 | $1.1602 | 12,037 | 01-28-2020 |
$ | $1.1799 | $1.21 | $1.24 | $1.15 | 32,368 | 01-27-2020 |
$ | $1.16 | $1.1474 | $1.219 | $1.1474 | 1,673 | 01-24-2020 |
$ | $1.2037 | $1.17 | $1.24 | $1.12 | 8,186 | 01-23-2020 |
$ | $1.22 | $1.2008 | $1.25 | $1.19 | 11,217 | 01-22-2020 |
$ | $1.11 | $1.19 | $1.2543 | $1.10 | 92,324 | 01-21-2020 |
$ | $1.18 | $1.10 | $1.18 | $1.10 | 30,866 | 01-20-2020 |
$ | $1.18 | $1.10 | $1.18 | $1.10 | 30,866 | 01-17-2020 |
$ | $1.27 | $1.16 | $1.27 | $1.14 | 24,052 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
AIkido Pharma Company Name:
SPEX Stock Symbol:
NASDAQ Market:
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Fin...
ALLSCHWIL, Switzerland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. ...
Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC) Spexis closed capital commitments totaling USD $7.5 million supporting Phase 3 ColiFin ® program in cystic fi...